Acute Ischemic Stroke study: Magnesium sulfate
Official title Intra-Arterial Magnesium Therapy After Mechanical Thrombectomy in Acute Ischemic Stroke
ClinicalTrials.gov ID: NCT06956521
What this study is testing
What is Magnesium sulfate?
Magnesium sulfate is an investigational medicine, given as an IV infusion (through a vein), being studied as a potential treatment for acute ischemic stroke.
Also referred to as MA 135 magnesium sulfate heptahydrate.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether injecting magnesium directly into the brain after a clot‑removal procedure is safe and well tolerated.
- Who it's for
- You may be able to join if you have a sudden stroke and need a clot‑removal procedure.
- What's involved
- You will receive a magnesium injection through a small tube during the clot‑removal procedure. You will be monitored for side effects afterward.
- Time commitment
- The study lasts only a few days, with a single procedure and a short follow‑up period.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 21 to 95
You may be able to join if
- Patient with acute cerebral ischemia due to ICA or MCA occlusion
- Major neurologic deficits: 6≤NIHSS≤20,
- Premorbid mRS 0 or 1, or 2
- Patient's clinical attending physician plans MT procedure as part of routine clinical care,
- undergo MT with a TICI 2a or better recanalization,
You likely can't join if
- Positive pregnancy test;
- those undergoing MT with a TICI \<2a revascularization;
- tandem occlusion of the cervical common or internal carotid artery; and
- people on therapeutic anticoagulation, as it is a relative contraindication to MT, and could be a confounding variable predisposing to intracranial...
- Second or third-degree heart block without a pacemaker in place,
- Technical inability to navigate micro-catheter to target clot,
See the full eligibility criteria
- Patient with acute cerebral ischemia due to ICA or MCA occlusion
- Major neurologic deficits: 6≤NIHSS≤20,
- Premorbid mRS 0 or 1, or 2
- Patient's clinical attending physician plans MT procedure as part of routine clinical care,
- undergo MT with a TICI 2a or better recanalization,
- Signed informed consent.
- Positive pregnancy test;
- those undergoing MT with a TICI \<2a revascularization;
- tandem occlusion of the cervical common or internal carotid artery; and
- people on therapeutic anticoagulation, as it is a relative contraindication to MT, and could be a confounding variable predisposing to intracranial hemorrhage including coagulation disorders, systematic hemorrhagic...
- Second or third-degree heart block without a pacemaker in place,
- Technical inability to navigate micro-catheter to target clot,
- Patient already enrolled in another experimental treatment trial. Exclusion criteria 1-3 are all contraindications to magnesium therapy,
- mRS\>2 caused by a history of prior stroke,
- Severe hepatic dysfunction, severe renal dysfunction (\<30 mL/min), increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal...
- Unsuitable for this clinical study assessed by researcher. people will not be excluded if they received IV t-PA as standard of care.
- patient is on neuromuscular blocking agents including depolarizing (succinylcholine) and nondepolarizing subtypes (rocuronium, vecuronium, etc);
- patient is taking any form of CNS depressant including barbiturates, narcotics, outside the setting of anesthesia or ICU sedation
- patients taking digoxin or other cardiac glycoside
The study team makes the final eligibility decision.
Where it is enrolling
- Houston, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 21 years to 95 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Houston, Texas, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.